Casdin Capital as of March 31, 2018
Portfolio Holdings for Casdin Capital
Casdin Capital holds 31 positions in its portfolio as reported in the March 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Loxo Oncology | 7.3 | $42M | 360k | 115.37 | |
Foundation Medicine | 7.2 | $41M | 520k | 78.75 | |
Sage Therapeutics (SAGE) | 7.1 | $40M | 250k | 161.07 | |
Blueprint Medicines (BPMC) | 5.6 | $32M | 348k | 91.70 | |
Spark Therapeutics | 5.4 | $31M | 463k | 66.59 | |
Agios Pharmaceuticals (AGIO) | 5.2 | $30M | 365k | 81.78 | |
Alnylam Pharmaceuticals (ALNY) | 5.2 | $30M | 250k | 119.10 | |
Global Blood Therapeutics In | 5.1 | $29M | 600k | 48.30 | |
Myokardia | 4.8 | $27M | 560k | 48.80 | |
Sangamo Biosciences (SGMO) | 4.7 | $27M | 1.4M | 19.00 | |
Fate Therapeutics (FATE) | 4.5 | $25M | 2.6M | 9.76 | |
Bluebird Bio (BLUE) | 4.3 | $25M | 145k | 170.75 | |
Codexis (CDXS) | 3.9 | $22M | 2.0M | 11.00 | |
Voyager Therapeutics (VYGR) | 3.8 | $21M | 1.1M | 18.79 | |
GenMark Diagnostics | 3.7 | $21M | 3.9M | 5.44 | |
Illumina (ILMN) | 3.0 | $17M | 72k | 236.42 | |
Evolent Health (EVH) | 2.8 | $16M | 1.1M | 14.25 | |
Jounce Therapeutics | 2.5 | $14M | 635k | 22.35 | |
Audentes Therapeutics | 2.4 | $14M | 450k | 30.05 | |
Beigene | 2.1 | $12M | 70k | 168.00 | |
iShares NASDAQ Biotechnology Index (IBB) | 1.8 | $10M | 95k | 106.74 | |
Clovis Oncology | 1.6 | $9.4M | 178k | 52.80 | |
Crispr Therapeutics (CRSP) | 1.1 | $6.2M | 135k | 45.71 | |
Cytomx Therapeutics (CTMX) | 1.0 | $5.9M | 208k | 28.45 | |
Editas Medicine (EDIT) | 0.8 | $4.4M | 133k | 33.15 | |
Neogen Corporation (NEOG) | 0.8 | $4.4M | 65k | 66.98 | |
OraSure Technologies (OSUR) | 0.7 | $4.1M | 240k | 16.89 | |
Celgene Corporation | 0.6 | $3.6M | 40k | 89.20 | |
Zai Lab (ZLAB) | 0.5 | $2.9M | 135k | 21.35 | |
Adverum Biotechnologies | 0.3 | $1.7M | 300k | 5.80 | |
Homology Medicines | 0.2 | $1.1M | 60k | 18.70 |